Video

Dr David Eagle: Progress in Hematology/Oncology Is Not Without Its Difficulties

Author(s):

For all the success the hematology/oncology space has seen over the past 20-plus years, difficult discussions now focus on paying for that care, explained David A. Eagle, MD, New York Cancer & Blood Specialists.

David A. Eagle, MD, chair of legislative affairs and patient advocacy at New York Cancer & Blood Specialists, explains how even progress has its drawbacks, as for all the success the hematology/oncology space has seen over the past 20-plus years, difficult discussions now focus on paying for that care.

Transcript

In the past 2-plus decades, what have been some of the biggest advancements in hematology/oncology?

The biggest advantages have clearly been on the scientific level: immunotherapy, targeted therapy. It begins with oncogenes, where we finally figured out, really, what makes a cancer a cancer. That’s clearly been the biggest progress in oncology. The problem is, as we talked about earlier, that that’s creating a natural tension between what we can do for patients and how we actually pay for that care.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Mansi Shah, MD
Dr John Mascarenhas
CK Wang, MD, COTA
Dr Pankit Vachhani
Screenshot of Ivo Abraham, PhD, RN, during a video interview
Merrill H. Stewart, MD
Dr John Mascarenhas
Carla Nester, MD, MSA, FASN, Stead Family Children's Hospital
Dr John Mascarenhas
Dr Xavier Leleu
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo